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 The Hospital Treatment Insights (HTI) database links admissions, diagnoses and 
procedures in the widely-used Hospital Episode Statistics (HES) database with 
dispensing information stored in hospital pharmacy systems for a subset of 43/153 acute 
hospital trusts in England. 
 Available from January 2010, HTI for the first time allows to analyse associations 
between diagnoses and hospital dispensing for individual patients in a relatively large 
number of NHS hospitals. 
 Successful linkage of diagnoses and dispensing depends on HES and the local 
pharmacy systems having a minimum number of patient identifiers in common such as 
the NHS number, date of birth, gender and postcode. While HES contains identifiers for 
every patient, hospital pharmacies only retain identifiers when drugs are ordered 
specifically for a named patient. Where medication is administered from drugs stored on 
the ward without informing the pharmacy about the receiving patient, the dispensation 
cannot be linked to HES and is therefore not captured in HTI. 
 Linkage of antibiotic dispenses was found to vary with individual antibiotic and ward 
settings. Capture of dispensing was good for specific antibiotics, but low linkage of 
highly-used treatments prevents HTI from being used for widespread antibiotic 
surveillance. 
 Principles and findings may be generalised to other drug classes. For each drug of 
interest, the proportion of dispenses captured should be taken into account when 
designing future studies using HTI. 
 
Prior presentations: 
An abstract for this study was displayed as a poster at the International Conference on 
Pharmacoepidemiology & Therapeutic Risk Management 2017 in Montreal. The study was 




Purpose: There has been a focus on stewardship programmes to curb inappropriate antibiotic 2 
prescribing and reduce antimicrobial resistance. In-hospital, patient-level prescribing linked to 3 
indication is needed to support surveillance, evaluation of stewardship initiatives, as well as 4 
other antibiotic research. We evaluated whether a novel dataset linking hospital pharmacy 5 
records to Hospital Episode Statistics (HES) data can be used for antibiotic research. 6 
 7 
Methods: Using the Hospital Treatment Insights (HTI) database, which links HES to pharmacy 8 
records from 43 out of 153 hospital trusts in England, we estimated the proportion of missed 9 
linkage and identified characteristics associated with missing data.  10 
 11 
Results: Linkage of antibiotics to patients was inconsistent and dependent on drug type and 12 
clinical setting, so that linkage for some specific antibiotics was high (80-100%), but overall, only 13 
27.6% (CI: 27.4% - 27.8%) for all antibiotics dispensed. Linkage was best for quinolones 14 
(62.6%; CI: 61.8% - 63.8%), but only 21.1% (CI: 21.1% - 21.2%) for penicillins. Linkage was 15 
lower for common antibiotics and in emergency departments, however 80% linkage was 16 
achieved for individual drugs like clindamycin, especially on wards with reduced ward stock use.  17 
 18 
Conclusions: For those antibiotics with high linkage, HTI might be used to study associations 19 
between indication, dispensing and outcomes. However, the majority of common antibiotics had 20 
insufficient linkage, likely due to extensive use of ward stocks. Therefore, HTI in its current form 21 
is not suitable for general antibiotic surveillance or evaluation of stewardship initiatives. For 22 







Owing to a continued rise in resistance1 and a slowing in the development of new antibiotics,2 29 
antimicrobial resistance (AMR) is currently poised to threaten the way we think about 30 
healthcare. A recognised risk factor for the emergence of resistance is excessive use of 31 
antibiotic treatment.3 To tackle this issue, antimicrobial stewardship (AMS) programmes are 32 
being implemented across the world to promote the effective use of antibiotics.4–7 In hospitals, 33 
appropriate and prudent treatment is particularly important, because the combination of 34 
vulnerable patients with high rates of co-morbidity, frequent antibiotic use2 and heavy 35 
dependence on broad-spectrum agents can create potent hotspots of AMR.3  36 
 37 
To facilitate effective and efficient AMR policies, further research on the uptake and impact of 38 
current hospital interventions is urgently needed. These efforts are hampered by the 39 
unavailability of longitudinal patient-level data due to a continued lack of wide-spread electronic 40 
prescribing in English secondary care.8 As a result, only aggregated data on hospital prescribing 41 
exists on a national level.9 While this aggregated information allows us to monitor overall trends 42 
in antibiotic usage, it prevents detailed enquiry into the association between indication and 43 
prescribing. Any impact specifically attributable to initiatives is difficult to discern from general 44 
trends in the population.3  45 
 46 
Linking information between the Hospital Episode Statistics (HES) database and the dispensing 47 
records stored in hospital pharmacy databases might offer a solution. However, success 48 
depends on these databases having a minimum number of patient identifiers in common such 49 
as the NHS number, date of birth, gender and postcode. While HES contains identifiers for 50 
every patient, hospital pharmacies only retain identifiers when drugs are ordered specifically for 51 
a named patient. Where a medication is instead stored on the ward, clinical personnel can 52 
  
administer it without informing the pharmacy about the receiving patient. In this case, no patient 53 
identifier is entered into the pharmacy system and the dispensation cannot be linked to HES.  54 
 55 
We set out to evaluate the extent of this issue and to explore whether a linkage approach can 56 
be utilised for research on antibiotic usage and surveillance in English hospitals. We described 57 
the proportion of observed antibiotic dispensing after linkage using the Hospital Treatment 58 
Insights (HTI) dataset, which links HES records with patient records from hospital pharmacies 59 
for 43 English trusts. We compared total dispensing within all HTI hospitals against aggregated 60 
pharmacy data on the hospital-level used by Public Health England.9 We estimated the 61 
proportion of dispensed antibiotics that were captured in the database and investigated factors 62 




Data sources 67 
 68 
Hospital Treatment Insights1 is a database of electronic health records from English secondary 69 
care. It is maintained by QuintilesIMS (https://www.quintilesims.com), a leading provider of 70 
information, services and technology for the healthcare industry. HTI links hospital patient 71 
records in the HES2 database with dispensing information stored in hospital pharmacy systems 72 
for a subset of 43 consenting trusts out of a total of 153 acute hospital trusts in England. In 73 
these participating trusts, HES already routinely captures hospital activity information such as 74 
demographics, admission and administrative data, diagnoses and procedures. Where 75 
dispensing data could be linked to patients, HTI retrospectively enriches the available HES data 76 
from 2010 onwards with patient-level data on brand, type, date and quantity of dispensed drugs. 77 
                                            
1 © 2017, re-used with the permission of IMS Health Limited.  All rights reserved. 
2 © 2017, re-used with the permission of NHS Digital. All rights reserved. 
  
Linkage was performed by NHS Digital as a trusted third party using a 15-step deterministic 78 
linkage algorithm (Supplement Table 1). Due to the data sharing agreement with NHS Digital, 79 
no information on the nature of the trusts (e.g. geography or specialty of the hospital) included 80 
in HTI was made available to the researchers. Therefore, data had to be treated as if it 81 
originated from a single hospital.  82 
 83 
Between 2010 and 2015, HTI included 7.7 million admitted hospital patients (Figure 1). For 3.6 84 
million (47.2%) of these patients, additional information on dispensed drugs was available. 3.9 85 
million (52.8%) patients had no medication information in HTI. Although some of these patients 86 
might genuinely not have been prescribed a drug, it is more likely that most of them received a 87 
drug but, for reasons exemplified below, dispensing could not be linked to the patient within HTI. 88 
Diagnoses and issued medications in HTI are not jointly recorded in the same IT system at the 89 
point of care. Instead, they are mapped at a later point in time by NHS Digital based on 90 
personal identifiers recorded in hospital pharmacy systems during dispensation. This can be 91 
done if medication is explicitly requested for a named patient. If instead the drug is bulk-92 
dispensed to the hospital ward for interim storage and used on demand, hospital pharmacy 93 
systems do not obtain feedback as to which patient eventually received the medication. Without 94 
this information, medication from ward stock cannot be linked and has to be excluded from HTI. 95 
This might happen for example in day case patients, who account for 35.1% of all inpatient 96 
episodes10. These day case patients bring in their own medication and may only require 97 
additional ward stock anaesthesia for procedures such as cataract surgery or endoscopy. They 98 
may therefore account for many of the patients without any medication information. A further 99 
clinical inpatient setting with possibly high ward stock usage and no additional drugs would be 100 
maternity care of women without comorbid disease. Whether HTI can indeed be used for 101 
antibiotic research on drug usage depends largely on the extent to which similar issues prevent 102 
HTI from accurately capturing antibiotic dispensing.11 103 
 104 
  
Aggregated reference levels of antibiotic dispensing in HTI hospitals were taken from the 105 
Hospital Pharmacy Audit (HPA) database, which has been used for antibiotic surveillance by 106 
Public Health England.9 Analogous to HTI, HPA is curated by QuintilesIMS and collected from 107 
hospital pharmacy systems, covering 99% of hospital beds in England.12 However, unlike HTI it 108 
does not contain patient specific information and is not, therefore, subject to data linkage. As a 109 
result, HPA includes bulk dispensing to wards excluded in HTI, allowing for it to be used as a 110 
measure of total hospital dispensing.  111 
 112 
Study design 113 
 114 
We conducted a retrospective cross-sectional study evaluating the proportion of antibiotic 115 
treatment that could be linked to a patient in English hospitals contributing to HTI between 1st 116 
April 2011 and 31st March 2015. Systemic antibiotics were defined using the classes J01 and 117 
J03A of the European Pharmaceutical Market Research Association’s anatomical classification 118 
used in both HTI and HPA.13 This definition is roughly equivalent to the class J01 in the World 119 
Health Organisation’s substance-based Anatomical Therapeutic Chemical (ATC) classification 120 
system, with a few notable exceptions like nitrofurantoin.14 Quantities were calculated as 121 
number of dispensed packs per month, without making an attempt to estimate the amount of 122 
defined daily doses contained in a pack. While this might lead to an over- or underestimation of 123 
the true proportion of linkage if linkage depends on dosage, packs provided a fast option to 124 
compare average linkage which can be easily extended to other classes of drugs.  125 
 126 
All antibiotic dispenses in HTI falling within the study period were extracted using the above 127 
definition. A quality control of the extract was performed, assessing it for clinically unlikely 128 
outliers due to data entry errors. Three antibiotic agents, ceftadizime, colistin, and 129 
sulfamethoxypyridazine, were excluded from the analysis, as some hospitals were found to 130 
report number of tablets dispensed instead of number of packs in a considerable number of 131 
  
cases. For other included antibiotics, the number of matching identifiers used for linkage was 132 
examined. 133 
 134 
Dispensing was then aggregated and compared to quantities reported in HPA for the same set 135 
of hospitals. The overall proportion of antibiotics that could be linked to a patient was estimated 136 
as the percentage of HPA dispensing found in HTI and appropriate 95%-confidence intervals 137 
(CI) were calculated using bootstrapping with 2,000 samples. Linkage was stratified by form, 138 
therapeutic agent and ward. Drugs were classified as oral, intravenous or another form (topical, 139 
lung administration, rectal, etc.) using EphMRA’s New Form Code. Antibiotic agents were 140 
grouped by antibiotic class and changes in linkage of these classes were compared over time. 141 
Dispensing was stratified by the five ward specialties with the highest observed usage in HPA: 142 
Accidents & Emergencies (A&E), general medicine, geriatrics, intensive care and respiratory 143 
medicine (thoracic medicine and respiratory clinics). Finally, linkage of individual antibiotic 144 
agents was contrasted across wards, using drugs indicated for methicillin-resistant 145 
Staphylococcus aureus (MRSA) infections by the British National Formulary as an example. 146 
 147 
Approval for this study was obtained by the Clinical Practice Research Datalink’s Independent 148 
Scientific Advisory Committee for MHRA database research (ISAC) as part of the protocol 149 
16/102. 150 
 151 




On average, 27.6% (CI: 27.4% - 27.8%) of all antibiotics dispensed in hospitals contributing to 156 
HTI could be linked to an individual patient (Table 1). The general strength of linkage was high, 157 
  
with more than 85% of the linkage based on NHS number and one or more additional identifiers 158 
(see Supplement Table 1).  159 
 160 
The proportion of packs linked to a patient depended on the form of the drug, the antibiotic 161 
agent and the type of ward. Respiratory medicine and geriatrics had an above average linkage 162 
of 48.3% (CI: 47.2% - 49.8%) and 39.6% (CI: 38.9% - 40.6%) respectively (Table 1). 163 
Emergency departments had much lower linkage of antibiotics, with 4.4% (CI: 4.3% - 4.4%) of 164 
dispensed antibiotics recorded in intensive care and 8.7% (CI: 8.7%- 8.7%) recorded in A&E. 165 
Linkage for general medicine was 13.2% (CI: 12.9% - 13.7%). Together, these five ward 166 
specialties were responsible for almost half of all antibiotic dispensing in the study period. 167 
Among other wards, exceptionally high linkage across all antibiotics was found in radiotherapy 168 
(89.0%, CI: 88.1% - 89.9%), whereas only 0.4% (CI: 0.4% - 0.4%) of antibiotics used in 169 
operating theatres were recorded. 170 
 171 
Oral antibiotics had a linkage of 37.2% (CI: 37.1% - 37.3%) while intravenous dispensing, 172 
accounting for almost two thirds of all antibiotic dispensing in hospitals, was less well captured 173 
with 21.9% (CI: 21.6% - 22.2%) linked to a patient. The highest linkage was achieved in other 174 
forms of antibiotics, but those only accounted for a small fraction of all dispenses. 175 
 176 
Regarding antibiotic groups, quinolones and carbapenems were recorded best, with 546,721 177 
(62.6%; CI: 61.8 % - 63.8%) respectively 278,668 (46.9%; CI: 46.6% - 47.2%) dispensed packs 178 
covered. Of all tetracyclines dispensed in hospital, 35.9% (CI: 35.8%-36.1%) could be linked to 179 
an individual patient. Cephalosporins and macrolides corresponded to the average with 391,553 180 
(28.5%; CI: 28.2% - 28.8%) and 639,042 (27.2%; CI: 27.1% - 27.3%) packs recorded in HTI. 181 
Penicillins could only be related to a patient for 21.1% (CI: 21.1% - 21.2%) of dispensed packs. 182 
This is especially noteworthy, as penicillins accounted for half of all packs dispensed. 183 
Furthermore, the proportion of penicillins observed in HTI decreased slightly over the study 184 
  
period (see Supplement Figure 1). In contrast, linkage of carbapenems increased at the 185 
beginning of 2013 from 44% to 52%. All other classes of antibiotics fluctuated around their initial 186 
levels. 187 
 188 
Looking into individual antibiotic agents, linkage ranged from 100.0% (CI: 74.1% - 100.0%) in 189 
telavancin, 97.4% (CI: 96.3% - 98.5%) in lymecycline and 92.1% in both linezolid (CI: 91.2% - 190 
93.0%) and moxifloxacin (CI: 90.7% - 93.5%) to 3% in cefuroxime (CI: 3.4% - 3.6%), gentamicin 191 
(CI: 3.3% - 3.4%) and penicillin G (CI: 3.0% - 3.1%) (Table 2). Limiting dispensing to specific 192 
wards influenced the proportion of linkage observed, as exemplified by the linkage of MRSA 193 
drugs in intensive care, general medicine, geriatrics and respiratory wards (Table 3). Higher 194 
proportions of linkage could be achieved for many drugs when looking solely at respiratory or 195 
geriatric wards. Drugs dispensed on general medicine wards, on the other hand, had almost 196 




Linkage of antibiotic dispenses varied with individual antibiotic and ward settings. Overall, in HTI 201 
a quarter of antibiotic dispensing was linked to an individual patient. Linkage of frequently used 202 
treatments was low, probably due to the fact that these drugs are less likely to be prescribed 203 
directly from pharmacy and often held as ward stock. As a consequence, coverage of high 204 
usage antibiotics like gentamicin, broad-spectrum penicillins and vancomycin was limited. 205 
Alternative treatments (e.g. clindamycin, daptomycin and tigecycline) had a much higher linkage 206 
across wards. The achieved proportion of linkage varied considerably depending on the ward 207 
where they were dispensed. Looking specifically at patients in wards like geriatrics or 208 
respiratory medicine improved the proportion of treatment observed and in multiple cases 209 
yielded linkage of more than 80%. Patterns of linkage changed little across the study period, 210 
with the exception of a sudden increase in linkage of carbapenems at the start of 2013. It is 211 
  
possible that the reductions in dispenses from ward stock represent the impact of stewardship 212 
initiatives promoting judicious use of carbapenems.  213 
 214 
This is the first study evaluating the representativeness and completeness of data recorded in 215 
HTI for research on antibiotic usage. We were able to identify and describe major factors 216 
influencing linkage of antibiotic treatment. However, the results of this study were limited in 217 
some ways. First, linkage was compared based on the number of dispensed packs to provide 218 
an easy methodology for estimating linkage quality. This approach may over- or underestimate 219 
the true proportion of linkage if linkage depends on the number of daily doses contained in a 220 
pack, e.g. if larger packs are less likely to be linked. If a study is to be performed on HTI, those 221 
results should therefore only act as a first indicator of feasibility and should be followed up by a 222 
detailed analysis based on daily doses. Second, the identity of the participating hospitals was 223 
not available to researcher and no hospital identifiers existed in the database at the time of 224 
study. Consequently, no statement could be made about variations in demographics or 225 
dispensing behaviour between individual hospitals. It is possible that findings in this study 226 
mainly reflect the effect of low antibiotic recording in a subset of hospitals. The inclusion of an 227 
anonymous trust identifier might reveal a subset of hospitals with high quality data linkage (e.g. 228 
due to local resistance patterns), which would allow investigating associations between drug 229 
usage and indications in more detail. Trust identifiers will be added to the database with the 230 
next data update in spring 2017. Finally, no evaluation of successful linkage could be 231 
performed. Linkage was conducted by NHS Digital as a trusted third party and we had no 232 
access to identifiable patient data. Consequently, no individual patient files could be revisited 233 
and records were treated as correctly linked where linkage was observed. False linkage could 234 
not be investigated in this study. If the linkage algorithm falsely mapped dispenses and patients 235 
in a large proportion of cases the findings in this study would overestimate true linkage.  236 
 237 
  
This study has highlighted some limitations, which must be taken into account for antibiotic 238 
research using HTI as a data source. Further evaluation is needed on HTI for other therapeutic 239 
agents with particular emphasis on the role of ward stock. Papers looking into the validity of 240 
prescribing databases in primary care in England generally found a high conformity of the 241 
quantity of drugs recorded when compared to external sources.16,17 High coverage of drugs was 242 
also found for a secondary care database in the Taiwanese insurance-based healthcare 243 
system.18 A study specifically investigating antibiotic prescribing in a Dutch secondary care 244 
database was able to obtain treatment for all patients with community-acquired pneumonia, 245 
although no validation of the obtained information was performed.19 The comparably low linkage 246 
found for some antibiotics in this study likely reflects a high use of ward stock dispensing for 247 
antibiotic treatment in English hospitals20 and a current inability to capture this dispensing. This 248 
conclusion is supported by findings on determining factors for linkage of dispensed drugs. 249 
Linkage was lowest across settings in which antibiotic usage tended to be either common or 250 
urgent, as is the case in A&E and intensive care. These situations potentially favour a higher 251 
utilisation of ward stock because of time constraints and efficiency gains. Linkage was generally 252 
higher for drugs like carbapenems and quinolones, which are used more cautiously and have 253 
been subject to increased stewardship measures over the last 15 years.21 Yet, the high levels of 254 
linkage in geriatrics and respiratory medicine, as compared to general medicine, cannot be fully 255 
explained by these differences.  256 
 257 
Although HTI in its current form does not seem to reflect a true picture of general antibiotic 258 
dispensing in secondary care, therefore preventing it from being used for widespread antibiotic 259 
surveillance, it has value for specific antibiotic research related to individual agents in specific 260 
ward settings, and may be used for broader studies where the missing drug usage can be 261 
estimated. There remains a pressing need for comprehensive and complete data to evaluate 262 
the intended and unintended impacts of AMS programmes in hospitals. However, although 263 
hospitals are clearly setting the course for e-prescribing,22 full adoption and availability for 264 
  
secondary use might still take years. For now, linking HES to pharmacy data provides a 265 
potential mechanism to investigate some patient-level drug usage across NHS hospitals. We 266 
have shown that this is already possible for a number of antibiotics, in particular in medical 267 
settings that rely less on ward stocks. Using hospital identifiers within HTI to identify sites with 268 
above-average linkage could be used to further improve coverage and to enable the analysis of 269 
more common antibiotics in HTI. Finally, reducing the reliance on ward stock in hospitals in the 270 
panel might be a way to continue increasing this linkage. The unexpected large differences in 271 
linkage rates between closely related wards, seen for example in general medicine and 272 
geriatrics, suggest that it is feasible to do so. Further research will be needed to understand and 273 
learn from the systematic differences in these ward level processes, the results of which may 274 
aid in elevating the status of antibiotics from drugs used in everyday medicine to a limited 275 
resource that requires prudent management. 276 
 277 
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Tables and Figures 
 
Table 1 - Total number of antibiotics dispensed and proportion linked to an individual patient 
 
     
 Total packs 
dispensed 
                      Patient-linked packs 
  n % of total (95%-CI) 
     
     
All 22,885,454 6,317,947    27.6 (27.4 – 27.8) 
     
Dispensing ward     
Accident & Emergency 2,389,513 207,842    8.7 (  8.7 –   8.7) 
General Medicine 4,039,748 532,728    13.2 (12.9 – 13.7) 
Geriatrics 1,364,470 540,037    39.6 (38.9 – 40.6) 
Intensive Care 1,222,121 53,311    4.4 (  4.3 –   4.4) 
Respiratory Medicine 1,154,135 557,398    48.3 (47.2 – 49.8) 
Other 12,715,467 4,426,631    34.8 (34.5 – 35.1) 
     
Form     
Intravenous 14,358,600 3,144,292    21.9 (21.6 – 22.2) 
Oral 8,518,627 3,169,344    37.2 (37.1 – 37.3) 
Other 8,227 4,311    52.4 (51.3 – 53.7) 
     
Antibiotic class     
Carbapenems 594,394 278,668    46.9 (46.6 – 47.2) 
Cephalosporins 1,376,450 391,553    28.4 (28.2 – 28.8) 
Macrolides 2,351,805 639,042 27.2 (27.1 – 27.3) 
Penicillins 12,026,953 2,538,705 21.1 (21.1 – 21.2) 
Quinolones 873,831 546,721    62.6 (61.8 – 63.8) 
Tetracyclines 575,250 206,723 35.9 (35.8 – 36.1) 
Others 5,086,771 1,716,535    33.7 (32.9 – 34.6) 
     









Table 2 - Linkage of individual antibiotic agents in HTI (Apr 2011 – Mar 2015) 
 
     
 
Total packs  
(as recorded in HPA)  
 
Patient – linked packs 
     
   n % of total 
     
     
Amikacin 44,119  19,569 44.35 
Amoxicillin 1,552,520  323,235 20.82 
Amoxicillin/Clavulanic Acid 2,318,864  595,729 25.69 
Ampicillin 516  103 19.92 
Ampicillin/Flucloxacillin 4,183  547 13.07 
Azithromycin 514,125  177,580 34.54 
Aztreonam 96,205  64,953 67.52 
Cefaclor 19,125  10,723 56.07 
Cefadroxil 1,751  676 38.60 
Cefalexin 280,941  100,843 35.89 
Cefixime 4,661  2,402 51.53 
Cefotaxime 179,128  29,663 16.56 
Cefpodoxime Proxetil 18  6 32.79 
Cefradine 17,945  7,103 39.58 
Ceftaroline Fosamil 70  41 59.40 
Ceftriaxone 506,527  226,346 44.69 
Cefuroxime 364,476  12,597 3.46 
Cefuroxime Axetil 1,806  1,152 63.77 
Chloramphenicol 154,784  91,252 58.95 
Cilastatin/Imipenem 46,884  12,082 25.77 
Ciprofloxacin 613,061  400,300 65.30 
Clarithromycin 1,575,692  370,088 23.49 
Clindamycin 378,721  233,180 61.57 
Dalfopristin/Quinupristin 89  85 95.14 
Daptomycin 55,118  47,221 85.67 
Demeclocycline 11,098  7,077 63.76 
Doripenem 0  0  –  
Doxycycline 518,694  159,485 30.75 
Ertapenem 246,339  137,143 55.67 
Erythromycin 262,324  91,374 34.83 
Flucloxacillin 1,546,681  382,220 24.71 
Fosfomycin 416  147 35.20 
Fusidic Acid 22,131  18,470 83.46 
Gentamicin 916,173  30,513 3.33 
Levofloxacin 165,184  82,624 50.02 
Linezolid 28,520  26,267 92.10 
Lymecycline 16,042  15,623 97.39 
Meropenem 301,170  129,442 42.98 
Minocycline 3,494  3,120 89.31 
Moxifloxacin 54,147  49,883 92.12 
Neomycin 9  8 92.38 
Norfloxacin 1,015  887 87.47 
Ofloxacin 40,424  13,026 32.22 
  
Oxytetracycline 13,919  12,410 89.16 
Penicillin G 186,962  5,663 3.03 
Penicillin V 553,564  179,302 32.39 
Piperacillin 0  0  –  
Piperacillin/Tazobactam 5,782,414  1,000,979 17.31 
Pivmecillinam 11,523  8,386 72.77 
Polymethyl M 460  0 0.00 
Rifabutin 1,777  1,395 78.54 
Sulfadiazine 1,896  1,414 74.58 
Sulfamethizole/Trimethoprim 633  217 34.27 
Sulfamethoxazole/Trimethoprim 170,395  106,382 62.43 
Teicoplanin 1,313,907  532,186 40.50 
Telavancin 27  27 100.00 
Temocillin 41,666  30,849 74.04 
Tetracycline 2,110  1,824 86.44 
Ticarcillin/Clavulanic Acid 28,060  11,694 41.67 
Tigecycline 9,894  7,184 72.61 
Tobramycin 136,028  86,051 63.26 
Trimethoprim 637,583  164,564 25.81 
Vancomycin 1,127,444  292,635 25.96 




















Table 3 - Differences in linkage of antibiotics used to treat methicillin resistant staphylococcus aureus infections 
 
         
 All wards   General medicine  Geriatrics  Respiratory 
 n 
% (95%-CI) 






         
         
         
Teicoplanin 
532,186   43,464  38,142  14,994 
40.5 (40.2 – 40.8)   24.0 (23.5 – 24.5)  65.5 (64.2 – 66.7)  71.5 (69.1 – 74.0) 
         
Vancomycin 
292,635   31,388  37,653  14,746 
26.0 (25.8 – 26.1)   18.9 (18.5 – 19.3)  50.4 (49.5 – 51.2)  36.1 (35.2 – 37.1) 
         
Clindamycin 
233,180   19,391  11,899  8,465 
61.6 (61.2 – 61.9)   37.1 (36.5 – 37.7)  68.5 (67.0 – 69.9)  79.9 (77.9 – 82.0) 
         
Daptomycin 
47,221   2,602  1,977  2,367 
85.7 (84.1 – 87.1)   40.2 (38.0 – 42.5)  80.4 (75.5 – 85.6)  99.3 (92.9  – 100.0) 
         
Linezolid 
26,267   1,587  1,297  1,884 
92.1 (91.2 – 93.0)   60.4 (58.4 – 62.4)  72.4 (69.7 – 75.1)  80.0 (77.2 – 82.8) 
         
Fusidic acid 
18,470   1,147  1,011  792 
83.5 (81.7 – 85.3)   55.7 (51.9 – 59.7)  61.2 (57.7 – 64.4)  78.4 (70.1 – 86.9) 
         
Tigecycline 
7,184   798  370  487 
72.6 (71.8 – 73.5)   52.9 (51.4 – 54.4)  71.7 (68.9 – 74.5)  65.2 (62.5 – 68.1) 
         
Ceftaroline 
41   10  0  0 
59.4 (51.4 – 68.0)   85.5 (85.5 – 85.5)  –  – 
         
Telavancin 
27   0  0  0 
100.0 (74.1 – 100.0)    –    –    –  
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